MoneyWorks4Me

Novartis receives USFDA nod for heart failure drug

10 Jul 2015 Evaluate

Novartis has received nod from the US health regulator for its heart failure treatment tablets - LCZ696 - and the company plans to launch the medicine in India. It will benefit many patients afflicted with heart failure.

The company plans to launch LCZ696 (sacubitril/valsartan) tablets under the brand name 'Entresto' in the US market. The tablets-LCZ696 will reduce risk of death from cardiovascular causes by 20 percent and will offer to patients a much greater opportunity to live longer and stay out of hospital.

Novartis is a world leader in the research and development of products to protect and improve health and well-being. The company has core businesses in pharmaceuticals, vaccines, consumer health, generics, eye care and animal health.

Novartis India Share Price

1596.85 45.75 (2.95%)
14-Aug-2026 16:01 View Price Chart
Peers
Company Name CMP
Redington 334.00
Amrapali Industries 36.65
Adani Enterprises 3040.00
Rashi Peripheral 834.50
PDS 371.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: